

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 May 2019 (09.05.2019)



(10) International Publication Number
WO 2019/089955 A1

(51) International Patent Classification:
C12N 5/0783 (2010.01) A61K 35/17 (2015.01)
C12N 5/09 (2010.01)

(21) International Application Number:
PCT/US2018/058747

(22) International Filing Date:
01 November 2018 (01.11.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
15/801,085 01 November 2017 (01.11.2017) US

(71) Applicant: THE UNITED STATES OF AMERICA,
AS REPRESENTED BY THE SECRETARY, DE-
PARTMENT OF HEALTH AND HUMAN SERVICES
[US/US]; National Institutes of Health, Office of Technol-
ogy Transfer, 6011 Executive Boulevard, Suite 325, MSC
7660, Bethesda, MD 20852-7660 (US).

(72) Inventors: CHILDS, Richard, W.; NHLBI, Hematology
Branch, Bldg 10 CRC Rm 35330 10 Center Drive, Bethesda,
MD 20892 (US). ALLAN, David, S.J.; Building 10-CRC,
Room 5-5264, 10 Center Drive, Bethesda, MD 20892 (US).


(74) Agent: GRAF, Susan, W.; Klarquist Sparkman, LLP, One
World Trade Center, Suite 1600, 121 SW Salmon Street,
Portland, OR 97204 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF PRODUCING MODIFIED NATURAL KILLER CELLS AND METHODS OF USE

FIG. 2



(57) Abstract: Disclosed herein are method of producing NK cells that include one or more heterologous nucleic acids. The methods include culturing a population of isolated NK cells in the presence of one or more cytokines to produce a population of activated NK cells. The population of activated NK cells are transduced with a viral vector comprising the one or more heterologous nucleic acids, for example by contacting the activated NK cells with viral particles including the viral vector. The resulting transduced NK cells are then cultured in the presence of one or more cytokines, and optionally in the presence of irradiated feeder cells, to produce a population of expanded transduced NK cells. Also disclosed are methods of treating a subject with a disorder (such as a tumor or hyperproliferative disorder) by administering to the subject NK cells produced by the methods described herein.

WO 2019/089955 A1

[Continued on next page]

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*